MGN 1601

Drug Profile

MGN 1601

Alternative Names: MGN-1601

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Mologen
  • Class Cancer vaccines; Cell therapies; Gene therapies; Tumour cell vaccines
  • Mechanism of Action Cell replacements; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Renal cancer

Most Recent Events

  • 09 Jun 2016 Suspended - Phase-I/II for Renal cancer (Late-stage disease) in Germany (Intradermal)
  • 16 Sep 2015 Phase-I/II development is ongoing for Renal cancer in Germany
  • 07 May 2014 Further efficacy data from a phase I/II trial in Renal cancer released by Mologen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top